Vaccination-induced skin-resident memory CD8+T cells mediate strong protection against cutaneous melanoma
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Memory CD8+ T cell responses have the potential to mediate long-lasting protection against cancers. Resident memory CD8+ T (Trm) cells stably reside in non-lymphoid tissues and mediate superior innate and adaptive immunity against pathogens. Emerging evidence indicates that Trm cells develop in human solid cancers and play a key role in controlling tumor growth. However, the specific contribution of Trm cells to anti-tumor immunity is incompletely understood. Moreover, clinically applicable vaccination strategies that efficiently establish Trm cell responses remain largely unexplored and are expected to strongly protect against tumors. Here we demonstrated that a single intradermal administration of gene- or protein-based vaccines efficiently induces specific Trm cell responses against models of tumor-specific and self-antigens, which accumulated in vaccinated and distant non-vaccinated skin. Vaccination-induced Trm cells were largely resistant to in vivo intravascular staining and antibody-dependent depletion. Intradermal, but not intraperitoneal vaccination, generated memory precursors expressing skin-homing molecules in circulation and Trm cells in skin. Interestingly, vaccination-induced Trm cell responses strongly suppressed the growth of B16F10 melanoma, independently of circulating memory CD8+ T cells, and were able to infiltrate tumors. This work highlights the therapeutic potential of vaccination-induced Trm cell responses to achieve potent protection against skin malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · cited 1×
“tion of antigens that drive tumor rejection have fostered the efficacy of cancer vaccines.(8,61) In this context, gene- and protein-based vaccination used in this study has demonstrated safety and immunogenicity in different clinical trials.”
BackgroundKochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Mackay, L. K., Rahimpour, A., Ma, J. Z., Collins, N., Stock, A. T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S. N., Stefanovic, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2744 · Cited by 1,331 · cited 2×
“(CD103)b7 (commonly referred to as CD103), which are responsible for avoiding tissue egress and facilitating interaction with epithelial barriers, respectively.(16,17) Trm cells are”
BackgroundSystemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963 · cited 1×
“Emerging evidence indicates that effective anti-tumor protection requires coordinated immunity across different tissues.(65,66) Furthermore, the ability of CD8C T cells to acquire a characteristic gene expression signature that enables them to become established in non-lymphoid tissues, is essential to defeat tumors.”
BackgroundQuezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898 · cited 1×
“Although encouraging, this study did not rule out the potential contribution of vaccinia virus-induced OVA-specific CD4C T cells,(35) which have been previously shown to acquire anti-tumor activity.(36) Therefore, the contribution of the vaccination-induced Trm cell compartment against melanoma has not been completely…”
ResultSkon, C. N., Lee, J.-Y., Anderson, K. G., Masopust, D., Hogquist, K. A., & Jameson, S. C. (2013) · Nature Immunology · doi:10.1038/ni.2745 · Cited by 817 · cited 1×
“(CD103)b7 (commonly referred to as CD103), which are responsible for avoiding tissue egress and facilitating interaction with epithelial barriers, respectively.(16,17) Trm cells are”
Background
Cited by
CD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 449
Local heroes or villains: tissue-resident memory T cells in human health and disease
Sasson, S. C., Gordon, C. L., Christo, S. N., Klenerman, P., & Mackay, L. K. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0359-1 · Cited by 111
“An understanding of the contribution of TRM cells in melanoma has the potential to direct the design of anti-melanoma vaccines for long-term protection, which has shown promise in animal models.(161)”
BackgroundZareie, P., Weiss, E. S., Kaplan, D. H., & Mackay, L. K. (2025) · Nature Immunology · doi:10.1038/s41590-025-02145-3 · Cited by 29
Tissue-resident memory T cells in antifungal immunity.
LeibundGut-Landmann, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693055 · Cited by 10
Metadata
- Authors
- Gálvez-Cancino, F., López, E., Menares, E., Díaz, X., Flores, C., Cáceres, P., Hidalgo, S., Chovar, O., Alcántara-Hernández, M., Borgna, V., Varas-Godoy, M., Salazar-Onfray, F., Idoyaga, J., & Lladser, A.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2018-03-19
- Volume
- 7
- Issue
- 7
- Pages
- e1442163
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2793854916
- Cited by
- 86
- References
- 17
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vaccination-induced skin-resident memory CD8+T cells mediate strong protection against cutaneous melanoma. https://app.cochat.ai/papers/10.1080/2162402x.2018.1442163
- The paper
- Gálvez-Cancino, F., López, E., Menares, E., Díaz, X., Flores, C., Cáceres, P., Hidalgo, S., Chovar, O., Alcántara-Hernández, M., Borgna, V., Varas-Godoy, M., Salazar-Onfray, F., Idoyaga, J., & Lladser, A. (2018). Vaccination-induced skin-resident memory CD8+T cells mediate strong protection against cutaneous melanoma. OncoImmunology. https://doi.org/10.1080/2162402x.2018.1442163
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.